What Drugs Should Not Be Taken With Lisinopril? A Complete Interaction Guide for Healthcare Providers

Lisinopril, an ACE inhibitor used to treat hypertension and heart failure, should not be co-administered with aliskiren in diabetic patients or those with renal impairment, and requires careful monitoring when combined with potassium-sparing diuretics, NSAIDs, and other RAS-blocking agents due to risks of hyperkalemia, acute renal failure, and excessive hypotension. Healthcare providers must understand the pharmacodynamic mechanisms underlying lisinopril interactions to prevent serious adverse events and optimize blood pressure management across diverse patient populations.

Understanding Lisinopril: Mechanism of Action and Why Interactions Matter

Lisinopril is an ACE inhibitor that works by blocking angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II. This mechanism reduces peripheral vascular resistance, decreases aldosterone secretion, and promotes sodium and water excretion through the kidneys. By inhibiting this single point in the renin-angiotensin-aldosterone system (RAAS), lisinopril achieves blood pressure reduction and cardiac remodeling benefits, particularly in heart failure and post-myocardial infarction populations.

However, this RAAS-modulating mechanism creates a pharmacological vulnerability: lisinopril alters electrolyte homeostasis, renal hemodynamics, and drug clearance pathways. Clinically, this means lisinopril interactions cluster around three major problems: (1) dual or excessive RAAS blockade leading to severe hypotension and acute kidney injury, (2) impaired drug clearance resulting in toxic accumulation of other agents, and (3) hyperkalemia—the most dangerous and preventable adverse outcome in ACE inhibitor therapy. Unlike many antihypertensives, lisinopril does not undergo hepatic metabolism via CYP450 pathways; it is renally eliminated unchanged. This renal elimination becomes critical in patients with renal impairment or when coadministered with drugs that further compromise glomerular filtration rate (GFR) or alter potassium handling.

Contraindicated Combinations: Absolute Avoidance Required

Lisinopril + Aliskiren (Tekturna)

The combination of lisinopril with aliskiren—a direct renin inhibitor—represents dual RAAS blockade at different enzymatic sites and is contraindicated in patients with diabetes or renal impairment (GFR <60 mL/min). Aliskiren blocks renin, the upstream enzyme that initiates the RAAS cascade, while lisinopril blocks ACE further downstream. This dual blockade creates a pharmacodynamic crisis: the system becomes unable to maintain renal perfusion pressure, leading to acute kidney injury (AKI), severe hyperkalemia, and refractory hypotension.

The FDA labeling explicitly warns against this combination in diabetic patients because diabetic nephropathy already compromises renal autoregulation. Studies using dual RAAS blockade in diabetic populations showed increased rates of hyperkalemia, hypotension, and renal function deterioration without additional cardiovascular benefit over monotherapy. For patients with diabetes requiring additional blood pressure control on lisinopril, alternative agent classes—calcium channel blockers, thiazide diuretics (with caution and monitoring), or beta-blockers—are preferred.

Major Interactions Requiring Careful Monitoring and Possible Dose Adjustment

Potassium-Sparing Diuretics (Spironolactone, Amiloride, Triamterene)

Potassium-sparing diuretics directly antagonize lisinopril's hyperkalemia risk profile through opposite mechanisms: ACE inhibitors reduce aldosterone, increasing urinary potassium excretion and serum K+ retention, while potassium-sparing agents block aldosterone directly, causing the kidneys to retain potassium. When combined, the net effect is profound hyperkalemia risk. Serum potassium can rise rapidly—often within 1–2 weeks of initiating combination therapy.

Clinical scenarios using this combination do exist: heart failure patients often benefit from an ACE inhibitor plus spironolactone for neurohormonal optimization (evidenced in landmark trials like RALES). However, this requires strict monitoring: baseline serum potassium and creatinine must be checked before initiation, then again at 3–5 days, 1–2 weeks, and then monthly for 3 months, with less frequent monitoring thereafter in stable patients. Potassium should remain <5.5 mEq/L. If hyperkalemia develops (K+ >6.0 mEq/L), the potassium-sparing agent is typically withdrawn, calcium gluconate is given for cardiac membrane stabilization if K+ >6.5 mEq/L, and insulin plus dextrose or sodium polystyrene sulfonate (Kayexalate) is administered to shift potassium intracellularly.

NSAIDs (Aspirin at High Doses, Ibuprofen, Naproxen, Indomethacin)

NSAIDs interact with lisinopril through multiple pathways. Prostaglandins maintain renal blood flow and GFR, particularly in volume-depleted states or chronic kidney disease. By inhibiting cyclooxygenase (COX), NSAIDs reduce prostaglandin synthesis in the kidney, causing vasoconstriction of the afferent arteriole. Lisinopril, by reducing angiotensin II-mediated efferent arteriolar vasoconstriction, becomes critically dependent on prostaglandin-mediated afferent vasodilation to maintain filtration pressure. Remove the prostaglandin effect with NSAIDs, and GFR collapses.

NSAIDs also attenuate lisinopril's antihypertensive effect by promoting sodium and water retention and activating the RAAS through renal hypoperfusion. The combination increases acute kidney injury risk, particularly in elderly patients, those with baseline renal impairment (eGFR <60), volume depletion, or dehydration. Low-dose aspirin (81 mg daily for cardiovascular protection) carries lower interaction risk than higher doses or other NSAIDs, but even low-dose aspirin may reduce lisinopril efficacy modestly. Patients on lisinopril requiring pain control should preferentially receive acetaminophen; if NSAIDs are necessary, use the lowest effective dose for the shortest duration, ensure euvolemia, and monitor serum creatinine and potassium at baseline and 1–2 weeks after NSAID initiation.

Lithium

ACE inhibitors reduce lithium clearance by decreasing glomerular filtration through multiple mechanisms: lisinopril reduces the glomerular filtration rate, increases proximal tubular reabsorption of lithium (through enhanced sodium reabsorption), and alters renal blood flow distribution. Lithium is cleared exclusively by the kidneys with no hepatic metabolism; any reduction in renal function translates directly to lithium accumulation.

Combined lisinopril and lithium therapy carries significant toxicity risk. Symptoms of lithium toxicity—tremor, confusion, ataxia, polyuria, cardiac arrhythmias—can develop insidiously. Baseline lithium levels should be checked before initiating lisinopril, then rechecked 3–5 days after ACE inhibitor addition, then weekly × 4 weeks, and monthly thereafter. Therapeutic lithium levels (0.5–1.2 mEq/L) may need adjustment downward—often by 25–50%. Any acute illness, dehydration, or NSAID use compounds toxicity risk. Patients should maintain consistent sodium and water intake. If feasible, alternative antihypertensive classes (calcium channel blockers, beta-blockers) are preferred in lithium-treated patients.

Other ACE Inhibitors and Angiotensin II Receptor Blockers (ARBs)

Dual ACE inhibitor therapy (lisinopril + enalapril or another ACE inhibitor) is redundant and provides no additional benefit. Combining lisinopril with ARBs like losartan represents dual RAAS blockade at different receptor sites and increases risks of hypotension, hyperkalemia, and acute kidney injury without superior cardiovascular outcomes compared to monotherapy. Meta-analyses have shown increased adverse events with dual RAS blockade. This combination should be avoided except in rare, closely monitored scenarios (e.g., heart failure with specific indications), and even then requires intensive monitoring of potassium, creatinine, and blood pressure.

Loop and Thiazide Diuretics

Initiating lisinopril in patients already on diuretics—or adding diuretics to established lisinopril therapy—carries hypotension risk. Diuretics cause volume depletion, which activates the RAAS. Lisinopril then blocks RAAS-mediated compensation, leading to excessive blood pressure reduction, syncope, acute kidney injury, and falls in elderly populations. Patients should be counseled to report dizziness, lightheadedness, or syncope. Blood pressure monitoring (home or clinical) should occur 3–5 days after dosing changes. If hypotension or renal dysfunction develops, diuretic dose reduction or temporary discontinuation may be necessary. Combination therapy is not contraindicated but requires careful titration and patient monitoring.

Gold Salts (Sodium Aurothiomalate, Aurothioglucose)

Gold compounds, used for rheumatoid arthritis, have been associated with nitritoid reactions when coadministered with ACE inhibitors. Nitritoid reactions—characterized by facial flushing, nausea, vomiting, hypotension, and rarely syncope—are thought to result from kinins accumulation (ACE inhibitors block kinin degradation) in the presence of gold-induced inflammatory responses. While rare, these reactions can be severe. Patients on gold therapy should not receive ACE inhibitors; alternative antihypertensives (calcium channel blockers, beta-blockers, direct-acting vasodilators) are safer choices.

MAO Inhibitors

ACE inhibitors and MAO inhibitors can produce excessive hypotension and renal function deterioration through overlapping vasodilatory and natriuretic mechanisms. The combination should be avoided. If psychiatric disease requires MAOI therapy and hypertension control is needed, alternative antihypertensive classes should be used, or adequate washout periods established.

Clinical Scenario 1: Elderly Patient with Hypertension, Heart Failure, and Renal Impairment

An 76-year-old male with a 15-year history of hypertension, New York Heart Association (NYHA) Class II heart failure, and chronic kidney disease Stage 3b (eGFR 38 mL/min/1.73m²) has been stable on lisinopril 20 mg daily, metoprolol succinate 47.5 mg daily, and furosemide 40 mg daily. His rheumatologist initiates naproxen 500 mg twice daily for osteoarthritis pain. Two weeks later, the patient reports increased dyspnea, reduced urine output, and ankle edema worsening. Laboratory work shows serum creatinine increased from 1.8 mg/dL to 2.3 mg/dL, and potassium 5.8 mEq/L (previously 5.1).

Clinical management: The NSAID (naproxen) is immediately discontinued. Renal perfusion is restored by ensuring adequate hydration (fluid status assessment and IV isotonic saline if needed). Lisinopril is temporarily held pending creatinine stabilization. An EKG is obtained to assess for hyperkalemia-related peaked T waves. If K+ remains >6.0 mEq/L, calcium gluconate 1 gram IV is administered, followed by insulin 10 units IV with 50 mL of 50% dextrose to shift potassium intracellularly. Creatinine and potassium are rechecked in 24–48 hours. Once stable (Cr baseline ±0.2 mg/dL, K+ <5.5), lisinopril is reintroduced at a reduced dose (e.g., 10 mg daily) with close monitoring. For pain control, acetaminophen up to 3 grams daily is substituted; if inadequate, topical NSAIDs or tramadol is considered with appropriate monitoring.

Clinical Scenario 2: Young Adult with Bipolar Disorder and Hypertension on Lithium

A 34-year-old female with bipolar I disorder, well-controlled on lithium carbonate 900 mg daily (serum level 0.9 mEq/L), presents with newly diagnosed hypertension (BP 158/96 mmHg). Lisinopril 10 mg daily is initiated. One week later, she reports tremor, nausea, and difficulty concentrating. Lithium level is checked and found to be 1.8 mEq/L (toxic range). Baseline creatinine was 0.9 mg/dL; current creatinine is 1.1 mg/dL.

Clinical management: Lisinopril is immediately held. The patient is advised to increase fluid and sodium intake (ensure euvolemia). Lithium is held for 24–48 hours while the elevated level is cleared, then restarted at a reduced dose (e.g., 600 mg daily, reduced from 900 mg). Lithium level is rechecked after 3–5 days. For blood pressure control, a calcium channel blocker (e.g., amlodipine 5 mg daily) is substituted, as these do not interact significantly with lithium and do not reduce renal function. Alternatively, a beta-blocker (metoprolol 50 mg daily) is considered. Blood pressure is monitored weekly × 4 weeks. Once psychiatric stability and renal function are confirmed stable, lisinopril may be reintroduced at low dose (5 mg daily) with close monitoring of lithium levels (3–5 days after initiation, then weekly × 4 weeks, then monthly).

Summary of Top Lisinopril Drug Interactions by Severity

• Aliskiren (Contraindicated in diabetes or renal impairment): Dual RAAS blockade → acute kidney injury, hyperkalemia, severe hypotension. Avoid.
• Spironolactone (Major, requires monitoring): Potassium retention → hyperkalemia. Monitor K+ at baseline, 3–5 days, 1–2 weeks, 1 month, then monthly. Target K+ <5.5 mEq/L.
• Amiloride (Major, requires monitoring): Potassium retention → hyperkalemia. Same monitoring protocol as spironolactone.
• NSAIDs including high-dose aspirin (Major, requires monitoring): Reduced renal perfusion, attenuated antihypertensive effect → acute kidney injury. Use lowest dose for shortest duration; monitor Cr and K+ at 1–2 weeks.
• Lithium (Major, requires monitoring): Reduced lithium clearance → lithium toxicity. Monitor lithium levels at baseline, 3–5 days, weekly × 4 weeks, then monthly. Consider dose reduction 25–50%.
• Losartan and other ARBs (Major, requires monitoring): Dual RAAS blockade → hyperkalemia, hypotension, acute kidney injury. Avoid unless compelling indication; monitor K+, Cr, BP closely.
• Loop and thiazide diuretics (Major, requires monitoring): Volume depletion exacerbates RAAS activation blockade → excessive hypotension, acute kidney injury. Monitor BP and symptoms; consider dose adjustment.
• Gold salts (Major, requires monitoring): Nitritoid reactions (flushing, hypotension, nausea). Avoid combination; use alternative antihypertensive.
• MAO inhibitors (Major, contraindicated in most settings): Excessive hypotension and renal deterioration. Avoid.
• Aripiprazole and other antipsychotics with alpha-adrenergic antagonism (Major, requires monitoring): Enhanced antihypertensive effect → hypotension. Monitor BP; may require lisinopril dose adjustment.

What Patients Should Tell Their Doctor When Starting Lisinopril

Patients should inform their healthcare provider of: (1) all current medications, including over-the-counter NSAIDs, herbal supplements, and nutritional products; (2) psychiatric medications, particularly lithium; (3) baseline kidney function and any history of kidney disease; (4) diabetes diagnosis; (5) recent or planned diuretic use; (6) history of angioedema; (7) pregnancy status or plans to become pregnant (ACE inhibitors are contraindicated in pregnancy); and (8) allergies to ACE inhibitors or other medications. Patients on lisinopril should be counseled to avoid potassium supplements and high-potassium salt substitutes unless specifically approved by their provider. They should also be instructed to report symptoms of hyperkalemia (weakness, palpitations, fainting), renal dysfunction (decreased urine output, swelling), or ACE inhibitor-specific adverse effects (persistent dry cough, facial swelling, difficulty breathing) immediately.

Monitoring Parameters and Intervals

At baseline before initiating lisinopril: Serum creatinine, estimated GFR (using MDRD or CKD-EPI equation), serum potassium, blood pressure (sitting and standing), and heart rate.

After lisinopril initiation (days 3–5): Blood pressure and symptom assessment (dizziness, syncope, fatigue).

After 1–2 weeks: Repeat serum creatinine and potassium; assess blood pressure response and tolerability.

After 1 month: Repeat serum creatinine and potassium if any concerns; otherwise, can extend interval.

Ongoing maintenance: Annual serum creatinine and potassium in stable patients; more frequent monitoring (every 3–6 months) if renal impairment present, on concurrent potassium-sparing agents, or if creatinine rises >30% from baseline.

Key Takeaways

• Lisinopril is contraindicated with aliskiren in diabetic patients or those with renal impairment (GFR <60) due to dual RAAS blockade causing acute kidney injury and severe hyperkalemia.
• Potassium-sparing diuretics, NSAIDs, and other RAS-blocking agents (ARBs) require intensive monitoring of serum potassium and creatinine when combined with lisinopril, as hyperkalemia and renal function deterioration are common and preventable with appropriate surveillance.
• Lithium levels require close monitoring and often downward dosing (25–50% reduction) when lisinopril is initiated, as ACE inhibitors reduce lithium clearance and can cause rapid toxicity.
• Initiating lisinopril in volume-depleted patients or those on diuretics carries substantial hypotension and acute kidney injury risk; careful titration, patient education on symptoms, and serial blood pressure monitoring are essential.
• Gold salts, MAO inhibitors, and certain antipsychotics should be avoided with lisinopril due to unacceptable adverse event profiles; alternative antihypertensive classes are safer in these populations.

Sources

• FDA Drug Labeling for Lisinopril via OpenFDA: https://open.fda.gov
• FDA Drug Labeling for Aliskiren (Tekturna) via OpenFDA: https://open.fda.gov
• National Institutes of Health Drug Information Portal: https://pubchem.ncbi.nlm.nih.gov
• American Heart Association/ACC Guidelines on Heart Failure Management: Accessed via https://www.acc.org
• UpToDate Clinical Database (subscription required) — ACE Inhibitor Drug Interactions
• Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for CKD Evaluation and Management: https://www.kidney.org
• NIH National Library of Medicine PubMed: https://pubmed.ncbi.nlm.nih.gov — Search: "ACE inhibitors drug interactions" and "lisinopril"

Check Your Full Medication List for Interactions

Lisinopril interactions extend beyond the major combinations covered here. Drug interactions are often patient-specific, depending on age, renal function, comorbidities, and polypharmacy burden. If you or a loved one takes lisinopril, do not rely on labels alone—use a comprehensive, up-to-date drug interaction checker to review your complete medication list against FDA labeling data. Visit checkdruginteractions.com to enter all your current medications and receive a detailed interaction report. Our database is powered by over 250,000 FDA drug labels from OpenFDA and the NIH National Library of Medicine, ensuring you have access to the most accurate, clinically relevant interaction information. Healthcare providers should also leverage this tool during patient visits to optimize safety and prevent serious adverse events.